Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer

Mark Christopher Markowski • 5 Jun 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, talks on advances in metastatic castration-resistant prostate cancer (mCRPC) presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, which focused on 177Lu-PSMA-617. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Mark Christopher Markowski

0:58
Sabizabulin in men with mCRPC who progressed on an androgen receptor targeting agent
Mark Christopher Markowski • 5 Jun 2022
0:45
Treatment sequencing for metastatic castration-resistant prostate cancer
Mark Christopher Markowski • 5 Jun 2022
0:53
OS and biomarker results from COMBAT: bipolar androgen therapy plus nivo for patients with mCRPC
Mark Christopher Markowski • 5 Jun 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals